Here are the 10-K annual reports from Hims & Hers Health, Inc. (HIMS) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow HIMS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HIMS filings page.
Hims & Hers Health, Inc. presents its Annual Report describing a fast‑growing, consumer‑focused telehealth and wellness platform built around subscription treatments for chronic conditions such as sexual health, hair loss, hormone health, weight loss, dermatology, and mental health. The company combines licensed Affiliated Medical Groups, wholly owned pharmacies, a 503B outsourcing facility, peptide manufacturing, and a new laboratory testing business to deliver personalized, mostly cash‑pay care in the U.S., U.K., EU, and Canada.
The report highlights growth initiatives including new menopause and testosterone offerings, comprehensive lab testing launched in 2025, and a definitive agreement to acquire Australia‑based Eucalyptus to expand into Australia and Japan. As of February 20, 2026, 219,561,143 Class A and 8,377,623 Class V shares were outstanding. Extensive sections outline a complex regulatory environment, compounded‑drug scrutiny, data‑privacy obligations, and detailed risk factors around competition, compliance, supply chain, and international expansion.